Follow-Up Study of Children with Precocious Puberty Treated with Cyproterone Acetate

A total of 1840 children and adolescents treated with cyproterone acetate (CPA) to block gonadal function, as a treatment for precocious puberty, short stature and other disorders, were registered to survey for the risk of developing hepatic tumors. Patients responding to follow-up numbered 1552 (85%). The cumulative dose and duration of CPA therapy for boys and girls were 110.4g and 2.6 years, and 122.9 g and 2.8 years, respectively. Among the 1552 patients, five hepatoma cases were found. Four underwent successful surgery and remain alive and well to date. Two of the 5 cases had been given more than 500g, the other 3 more than 1000 g, of CPA. Three had also been given androgens before CPA administration. Although further follow-up is necessary to monitor for the development of adenoma and hepatoma, the risk of developing these tumors among patients to whom limited doses of CPA were administered appears to be negligible. J Epidemiol, 1997 ; 7 : 173-178.

[1]  D. Thomas,et al.  Multicentre international liver tumour study protocol of the case‐control study on hepatocellular cancer , 1996, Pharmacoepidemiology and Drug Safety.

[2]  T. Rabe,et al.  Cyproterone Acetate , 1996, Drug safety.

[3]  J. Topinka,et al.  Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver. , 1995, Carcinogenesis.

[4]  P. Kasper,et al.  In vitro mutagenicity studies on cyproterone acetate using female rat hepatocytes for metabolic activation and as indicator cells. , 1995, Carcinogenesis.

[5]  W. Kuhnz,et al.  Identification of 3 alpha-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro. , 1995, Carcinogenesis.

[6]  J. Topinka,et al.  DNA-damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. , 1995, Carcinogenesis.

[7]  A. Martelli,et al.  DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. , 1995, Carcinogenesis.

[8]  T. Rüdiger,et al.  Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol , 1995, The Lancet.

[9]  A. Tanae,et al.  Three cases of hepatocellular carcinoma among cyproterone users , 1994, The Lancet.

[10]  S. Culine,et al.  Hepatocellular Carcinoma During Hormonotherapy for Prostatic Cancer , 1994, American journal of clinical oncology.

[11]  L. Crinò,et al.  Cyproterone acetate: hepatotoxicity and prostatic cancer treatment. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E. Deml,et al.  Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. , 1993, Carcinogenesis.

[13]  J. Topinka,et al.  Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. , 1993, Carcinogenesis.

[14]  H. Greim,et al.  Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in gamma-glutamyltranspeptidase-positive cells. , 1992, Carcinogenesis.

[15]  R. Catane,et al.  Hepatitis due to cyproterone acetate. , 1992, European journal of cancer.

[16]  N. Nagasue,et al.  Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors , 1991, Cancer.

[17]  B. Parys,et al.  Severe hepatocellular dysfunction following cyproterone acetate therapy. , 1991, British journal of urology.

[18]  J. Gaer,et al.  Hepatocellular carcinoma and treatment with cyproterone acetate. , 1991, British Journal of Urology.

[19]  N. Mcintyre,et al.  Severe hepatitis caused by cyproterone acetate. , 1990, Gut.

[20]  H. Lévesque,et al.  FULMINANT HEPATITIS DUE TO CYPROTERONE ACETATE , 1989, The Lancet.

[21]  N. Mulder,et al.  Hepatocellular damage by cyproterone acetate. , 1986, European journal of cancer & clinical oncology.

[22]  P. Johnson,et al.  Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. , 1983, British Journal of Cancer.